EN | JPN | FR
EN | JPN | FR
Leading the way in posterior segment research.
Ora’s Posterior Segment Division represents the fastest growing department of Ora, comprised of more than 100 people, globally situated, operations team experienced in a myriad of retinal indications. With over 35 active programs, Ora’s Posterior Segment division is conducting more retina studies than any other singular CRO.
The team includes an on-staff retina surgeon, a therapeutic area head with 20+ years of ophthalmic drug development experience, and an operations head that has conducted or overseen over 30 retina trials.
Ora’s Posterior Segment team also maintains relationships with the industry’s top retinal imaging centers and develops novel endpoints to better understand and treat diseases of the retina.
Illumination of the retina
Achromatopsia
Choroideremia
Cystoid Macular Edema
Diabetic Macular Edema
Diabetic Macular Ischemia
Diabetic Retinopathy
Dry Age-Related Macular Degeneration (Dry AMD), including Geographic Atrophy
Glaucoma & Neuroprotection
Leber Congenital Amaurosis (LCA)
Leber Hereditary Optic Neuropathy (LHON)
Myopia Progression
Proliferative Vitreoretinopathy
Retinal Vein Occlusion (Branch [BRVO] and Central [CRVO])
Retinitis Pigmentosa
Retinoschisis
Stargardt Disease
Uveal Melanoma
Uveitis (Anterior, Intermediate, Posterior)
Vitreomacular Adhesion
Wet Age-Related Macular Degeneration (Wet AMD)
As Senior Vice President of Ora’s Posterior Segment Division, Keith Lane leads clinical operations and regulatory strategy.
Having spent over 20 years at Ora, Keith has held several senior management positions, including leading Ora’s Research & Development department where he directed the creation and validation of clinical models, endpoints, and trial processes for nearly a decade.
Keith also led the development and launch of Ora’s Visual Navigation Challenge (Ora-VNC™).
Senior Vice President, Posterior Segment
Ora’s Visual Navigation Challenge (Ora-VNC™).
Ora is at the forefront of Retina and Posterior Ocular research, executing multiple programs and developing both imaging and functional endpoints to help promising novel therapeutic drugs and devices get to market.
“Ora has proven to be an enthusiastic and highly effective partner … Ora’s great reputation and track history of placing high level research projects was a major factor in choosing them for our partnership.”
Arman Farr, MD
Ora LLC websites use cookies. By continuing to browse the site you are agreeing to our use of cookies.
For more details about cookies and their use, please see our Privacy Policy.
